RAD51

RAD51
Conway, A.B., Lynch, T.W., Zhang, Y., Fortin, G.S., Symington, L.S., Rice, · Attribution · source
Name	RAD51
Uniprot	P38398
Organism	Homo sapiens

RAD51 RAD51 is a eukaryotic recombinase central to homologous recombination and maintenance of genomic stability. First characterized in Saccharomyces cerevisiae genetic screens and later cloned from Homo sapiens laboratories, RAD51 has been studied across model organisms including Drosophila melanogaster and Mus musculus. Its dysfunction links basic research institutions, clinical oncology centers, and pharmaceutical efforts toward targeted therapies.

Function and Biological Role

RAD51 mediates strand exchange between homologous DNA duplexes during repair of DNA double-strand breaks, replication fork restart, and meiotic recombination. In mitotic cells from Homo sapiens and Mus musculus, RAD51 assembles onto single-stranded DNA to form nucleoprotein filaments that perform homology search and strand invasion, complementing machineries characterized in Saccharomyces cerevisiae studies. RAD51 activity coordinates with cell cycle regulators discovered in screens at institutions like the National Institutes of Health and the European Molecular Biology Laboratory to ensure timing with S and G2 phases, minimizing chromosomal aberrations observed in clinical cytogenetics units.

Structure and Mechanism

The RAD51 protein adopts an ATPase core shared with RecA-family recombinases first delineated by structural biology teams at centers such as the Max Planck Society and the Cold Spring Harbor Laboratory. High-resolution cryo-EM and X-ray crystallography from research groups at University of Cambridge and Stanford University revealed a helical filament architecture binding ATP and single-stranded DNA. Mechanistically, RAD51 cycles through ATP-bound, ADP-bound, and nucleotide-free states to promote filament polymerization and depolymerization, a process biochemically dissected in laboratories at Massachusetts Institute of Technology and the Weizmann Institute of Science. Mutational analyses performed by investigators at the University of Oxford linked conserved Walker motifs to ATP hydrolysis essential for strand exchange.

Regulation and Interacting Proteins

RAD51 function is tightly regulated by post-translational modifications and protein interactions uncovered by proteomics groups at Harvard University and the European Bioinformatics Institute. Mediators such as BRCA2 identified by researchers at University of Cambridge and Memorial Sloan Kettering Cancer Center recruit RAD51 to resected DNA ends; paralogs including RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3 form complexes characterized by teams at the Salk Institute and Johns Hopkins University that stabilize filament formation. Checkpoint kinases like ATM and ATR, investigated in projects at the Rockefeller University and Cold Spring Harbor Laboratory, modulate RAD51 via phosphorylation cascades involving CHK1 and CHK2 signaling pathways described in studies at the Dana-Farber Cancer Institute. Ubiquitin and SUMO conjugation enzymes from work at CNIO and Institut Curie further tune RAD51 turnover in response to genotoxic stress.

Clinical Significance and Disease Associations

Altered RAD51 expression and mutations are implicated in hereditary and sporadic cancers analyzed in cohorts from National Cancer Institute trials and oncology consortia such as The Cancer Genome Atlas. Germline variants in RAD51-interacting pathways including BRCA1 and BRCA2, reported by clinical genetics units at St. Jude Children's Research Hospital and Royal Marsden Hospital, confer breast and ovarian cancer susceptibility and influence therapeutic responses. RAD51 overexpression correlates with chemoresistance in studies from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, while RAD51 deficiency manifests in genomic instability syndromes described by pediatric centers like Great Ormond Street Hospital. Tumor biology research at Fred Hutchinson Cancer Research Center and Vanderbilt University has linked RAD51 dysregulation to metastasis and treatment outcome metrics used in clinical trials.

Role in DNA Repair Pathways

RAD51 is a linchpin of homologous recombination repair interacting with resection machineries mapped by collaborative efforts at European Molecular Biology Laboratory and Cold Spring Harbor Laboratory. In the repair cascade, nucleases characterized at Max Planck Institute for Molecular Genetics and helicases from University College London generate the single-stranded DNA substrate on which RAD51 acts; the strand invasion step is coordinated with cohesin and synaptonemal complex factors studied at University of California, San Francisco and University of Edinburgh. RAD51 also participates in replication fork protection and template switching processes elucidated by teams at Imperial College London and National Taiwan University Hospital, interfacing with translesion synthesis and non-homologous end joining pathways investigated at University of Michigan and University of Toronto.

Experimental and Therapeutic Applications

RAD51 serves as a tool in genome editing, synthetic lethality screens, and drug discovery pipelines at biotechnology firms and academic centers like Genentech, CRISPR Therapeutics, and Broad Institute. Small molecules and peptides targeting RAD51 filament dynamics have been developed in preclinical studies by groups at AstraZeneca and Bristol-Myers Squibb to sensitize tumors to PARP inhibitors trials coordinated by National Cancer Institute. Diagnostic assays measuring RAD51 foci by immunofluorescence are employed in translational labs at Mayo Clinic and Karolinska Institutet to predict homologous recombination deficiency and guide precision oncology. Emerging approaches exploit RAD51-mediated recombination for therapeutic gene correction explored by investigators at University of Pennsylvania and Children's Hospital of Philadelphia.

Category:DNA repair proteins